X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

- test

Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer

Reduced-dose cabazitaxel is non-inferior to the standard dose for patients with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel, according to... Read More

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

The addition of abiraterone acetate and prednisone (AAP) or docetaxel and prednisone (DocP) to standard of care (SOC) may improve... Read More

Statin-use May Decrease Mortality Risk in Prostate Cancer

Patients who take statins after prostate cancer (PC) diagnosis may have a reduced risk of mortality, according to a study published in... Read More

Abiraterone Plus Prednisone, Androgen-deprivation for Metastatic Prostate Cancer

Newly diagnosed patients with metastatic, castration-sensitive prostate cancer may have significantly prolonged overall survival (OS) and radiographic progression-free survival (PFS)... Read More

Genomic Sequencing May Help To Determine Prognosis in High-risk Prostate Cancer

Genomic testing and immunomodulation may help to improve outcomes among patients with prostate cancer, according to a study published in... Read More

Active Surveillance and Watchful Waiting for Low-Risk Prostate Cancer

Active surveillance and watchful waiting are emerging as important management options for men diagnosed with early-stage prostate cancer. Patients do not,... Read More

Prostatectomy May Not Improve All-cause Mortality vs Observation

Evidence from a long term follow-up published in the New England Journal of Medicine suggests that prostatectomy may not improve... Read More

Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Improvements in the technology used to capture circulating tumor cells (CTCs) may offer a better way to understand prostate cancer... Read More

Early Taxane Switching May Improve PSA Response Rates in Prostate Cancer

Early switching from docetaxel to cabazitaxel or vice versa may lead to improved prostate-specific antigen (PSA) response rates, according to... Read More

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

An automated bone scan index (aBSI) at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate... Read More

1 2 3